S&P 500   4,076.57
DOW   34,395.01
QQQ   293.72
Is Apple Going To Rally Into Year End?
Copper Exploration Heating Up (Ad)
25 Ways to Improve Your Financial Situation in 1 Hour
Are the Short Sellers Still Right About Mullen Automotive stock? 
YIKES! 220 Pounds of Graphite in Each EV Battery? (Ad)
La-Z-Boy Reclines To More Comfortable Levels 
Is The Recovery Rally Here For SoFi?
YIKES! 220 Pounds of Graphite in Each EV Battery? (Ad)
Biden administration presses senators to avert rail strike
Trump Org. defense lawyer scolded for using struck testimony
S&P 500   4,076.57
DOW   34,395.01
QQQ   293.72
Is Apple Going To Rally Into Year End?
Copper Exploration Heating Up (Ad)
25 Ways to Improve Your Financial Situation in 1 Hour
Are the Short Sellers Still Right About Mullen Automotive stock? 
YIKES! 220 Pounds of Graphite in Each EV Battery? (Ad)
La-Z-Boy Reclines To More Comfortable Levels 
Is The Recovery Rally Here For SoFi?
YIKES! 220 Pounds of Graphite in Each EV Battery? (Ad)
Biden administration presses senators to avert rail strike
Trump Org. defense lawyer scolded for using struck testimony
S&P 500   4,076.57
DOW   34,395.01
QQQ   293.72
Is Apple Going To Rally Into Year End?
Copper Exploration Heating Up (Ad)
25 Ways to Improve Your Financial Situation in 1 Hour
Are the Short Sellers Still Right About Mullen Automotive stock? 
YIKES! 220 Pounds of Graphite in Each EV Battery? (Ad)
La-Z-Boy Reclines To More Comfortable Levels 
Is The Recovery Rally Here For SoFi?
YIKES! 220 Pounds of Graphite in Each EV Battery? (Ad)
Biden administration presses senators to avert rail strike
Trump Org. defense lawyer scolded for using struck testimony
S&P 500   4,076.57
DOW   34,395.01
QQQ   293.72
Is Apple Going To Rally Into Year End?
Copper Exploration Heating Up (Ad)
25 Ways to Improve Your Financial Situation in 1 Hour
Are the Short Sellers Still Right About Mullen Automotive stock? 
YIKES! 220 Pounds of Graphite in Each EV Battery? (Ad)
La-Z-Boy Reclines To More Comfortable Levels 
Is The Recovery Rally Here For SoFi?
YIKES! 220 Pounds of Graphite in Each EV Battery? (Ad)
Biden administration presses senators to avert rail strike
Trump Org. defense lawyer scolded for using struck testimony

Miromatrix Medical - MIRO Stock Forecast, Price & News

$4.15
-0.04 (-0.95%)
(As of 12/1/2022 12:00 AM ET)
Add
Compare
Today's Range
$4.10
$4.15
50-Day Range
$3.53
$4.45
52-Week Range
$2.02
$7.30
Volume
2,305 shs
Average Volume
34,784 shs
Market Capitalization
$86.74 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$9.00

Miromatrix Medical MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
116.9% Upside
$9.00 Price Target
Short Interest
Healthy
1.73% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.48) to ($1.17) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.06 out of 5 stars

Medical Sector

618th out of 1,047 stocks

Biological Products, Except Diagnostic Industry

97th out of 173 stocks

About Miromatrix Medical

Miromatrix Medical Inc., a life sciences company, develops a novel technology for bioengineering fully transplantable organs. Its proprietary technology is a platform that uses a two-step method of decellularization and recellularization designed to remove the porcine cells from the organs obtained from pigs and replace them with unmodified human cells. The company has collaborations with The Mayo Clinic, Mount Sinai Hospital, and The Texas Heart Institute. The company was formerly known as TayTech, Inc. Miromatrix Medical Inc. was incorporated in 2009 and is headquartered in Eden Prairie, Minnesota.

Receive MIRO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Miromatrix Medical and its competitors with MarketBeat's FREE daily newsletter.

MIRO Stock News Headlines

The single greatest medical breakthrough of all time?
We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.
Earnings Preview: Miromatrix Medical
Miromatrix to Report Third Quarter 2022 Financial Results
The single greatest medical breakthrough of all time?
We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.
Miromatrix Medical Inc. Misses Q2 EPS by 7c
Miromatrix Medical Inc
Miromatrix Medical: Q2 Earnings Insights
See More Headlines
Receive MIRO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Miromatrix Medical and its competitors with MarketBeat's FREE daily newsletter.

MIRO Company Calendar

Last Earnings
11/14/2022
Today
12/02/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
3/29/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:MIRO
Fax
N/A
Employees
36
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$9.00
High Stock Price Forecast
$9.00
Low Stock Price Forecast
$9.00
Forecasted Upside/Downside
+116.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-14,670,000.00
Net Margins
-91,903.22%
Pretax Margin
-91,903.22%

Debt

Sales & Book Value

Annual Sales
$30,000.00
Book Value
$1.57 per share

Miscellaneous

Free Float
19,875,000
Market Cap
$86.74 million
Optionable
Not Optionable
Beta
-0.62

Key Executives

  • Dr. Jeffrey James Ross Ph.D. (Age 46)
    CEO & Director
    Comp: $566.75k
  • Mr. Brian D. Niebur CPA (Age 58)
    CFO & VP of Fin.
    Comp: $349.58k
  • Mr. James M. Douglas (Age 49)
    CFO & Sec.
  • Mr. Tom Emig
    VP of People & Culture
  • Dr. John Joseph Barry Ph.D.
    VP of R&D













MIRO Stock - Frequently Asked Questions

Should I buy or sell Miromatrix Medical stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Miromatrix Medical in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" MIRO shares.
View MIRO analyst ratings
or view top-rated stocks.

What is Miromatrix Medical's stock price forecast for 2023?

1 equities research analysts have issued 12-month price targets for Miromatrix Medical's shares. Their MIRO share price forecasts range from $9.00 to $9.00. On average, they anticipate the company's stock price to reach $9.00 in the next year. This suggests a possible upside of 116.9% from the stock's current price.
View analysts price targets for MIRO
or view top-rated stocks among Wall Street analysts.

How have MIRO shares performed in 2022?

Miromatrix Medical's stock was trading at $4.69 at the start of the year. Since then, MIRO stock has decreased by 11.5% and is now trading at $4.15.
View the best growth stocks for 2022 here
.

When is Miromatrix Medical's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 29th 2023.
View our MIRO earnings forecast
.

How were Miromatrix Medical's earnings last quarter?

Miromatrix Medical Inc. (NASDAQ:MIRO) issued its quarterly earnings data on Monday, November, 14th. The company reported ($0.37) EPS for the quarter, missing analysts' consensus estimates of ($0.33) by $0.04. The business earned $0.01 million during the quarter, compared to analysts' expectations of $0.01 million. Miromatrix Medical had a negative net margin of 91,903.22% and a negative trailing twelve-month return on equity of 65.37%.

When did Miromatrix Medical IPO?

(MIRO) raised $32 million in an initial public offering (IPO) on Thursday, June 24th 2021. The company issued 4,000,000 shares at $7.00-$9.00 per share. Craig-Hallum Capital Group acted as the underwriter for the IPO.

What is Miromatrix Medical's stock symbol?

Miromatrix Medical trades on the NASDAQ under the ticker symbol "MIRO."

Who are Miromatrix Medical's major shareholders?

Miromatrix Medical's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Gagnon Securities LLC (3.79%), Vanguard Group Inc. (2.05%), Gagnon Advisors LLC (1.82%), Sweet Financial Partners LLC (1.30%), Legacy Wealth Asset Management LLC (0.24%) and Envestnet Asset Management Inc. (0.23%).

How do I buy shares of Miromatrix Medical?

Shares of MIRO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Miromatrix Medical's stock price today?

One share of MIRO stock can currently be purchased for approximately $4.15.

How much money does Miromatrix Medical make?

Miromatrix Medical (NASDAQ:MIRO) has a market capitalization of $86.73 million and generates $30,000.00 in revenue each year. The company earns $-14,670,000.00 in net income (profit) each year or ($1.39) on an earnings per share basis.

How can I contact Miromatrix Medical?

The official website for the company is www.miromatrix.com. The company can be reached via phone at 952-942-6000 or via email at ir@miromatrix.com.

This page (NASDAQ:MIRO) was last updated on 12/2/2022 by MarketBeat.com Staff